-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Adient, Lowers Price Target to $29

Benzinga·08/06/2026 18:55:31
Listen to the news
UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Buy and lowers the price target from $34 to $29.